Metabolic

Case study

Tackling the specificities of NASH/MASH clinical trials

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating chronic illness that significantly impairs patients' quality of life, affecting their daily routines, work, and...

Article

The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

Metabolic Scientific advice

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally and is the most severe...

Subscribe to our newsletter

Rare disease clinical research: it is time to tackle what...

Biotech and eCOA vendor: A shared mindset

The client’s voice: why they consistently choose Kayentis

Why you should join Kayentis

Rethinking pediatric clinical trials: guidelines from pediatric experts

Overcoming challenges in long-lasting pediatric clinical trials – Insights from...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Kayentis Europe
19 bis, chemin du vieux Chêne
38240 Meylan
France
Phone: +33 (0)4 76 00 54 20

Kayentis US
186 South Street
Suite 600
Boston, Massachusetts 02111
USA